Neurotech International (ASX:NTI) Total Liabilities : A$0.28 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Neurotech International Total Liabilities?

Neurotech International's Total Liabilities for the quarter that ended in Dec. 2023 was A$0.28 Mil.

Neurotech International's quarterly Total Liabilities increased from Dec. 2022 (A$0.37 Mil) to Jun. 2023 (A$1.35 Mil) but then declined from Jun. 2023 (A$1.35 Mil) to Dec. 2023 (A$0.28 Mil).

Neurotech International's annual Total Liabilities declined from Jun. 2021 (A$1.14 Mil) to Jun. 2022 (A$0.59 Mil) but then increased from Jun. 2022 (A$0.59 Mil) to Jun. 2023 (A$1.35 Mil).

Neurotech International Total Liabilities Historical Data

The historical data trend for Neurotech International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International Total Liabilities Chart

Neurotech International Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

0.36

0.73

1.14

0.59

1.35

Neurotech International Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial										0.20	0.59	0.37	1.35	0.28

Neurotech International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Neurotech International's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.347	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.35

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	5.309	-	3.962
	=	1.35

Neurotech International's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.276	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.28

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	5.07	-	4.795
	=	0.28

Neurotech International Total Liabilities Related Terms

Thank you for viewing the detailed overview of Neurotech International's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurotech International (ASX:NTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009

Website

https://www.neurotechinternational.com

Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend • 11-12-2014

By Dividend Dividend • 06-25-2013

9 Stocks with Double-Digit Yields and Buy or Better Recommendations

By Dividend Dividend • 07-17-2013

18 Stocks with Very High Yields (More Than 10%) and Earnings Growth

By Dividend Dividend • 12-20-2012

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson • 11-09-2013

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend • 01-17-2013

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend • 08-17-2013